Taiwan 'breakthrough therapy' drugs to enter clinical trials

04/12/2017 09:28 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Los Angeles, April 12 (CNA) Two new drugs, developed by a Taiwanese company for the treatment of schizophrenia and designated by the U.S. Food and Drug Administration (FDA) as breakthrough therapy, will undergo late stage trials this year, according to the company's founder and CEO.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.